leptospirosis : update on management

42
LEPTOSPIROSIS UPDATE Dr Vasif MC GMKMCH

Upload: vasif-mayan

Post on 08-Feb-2017

171 views

Category:

Health & Medicine


2 download

TRANSCRIPT

Page 1: Leptospirosis : update on management

LEPTOSPIROSIS UPDATEDr Vasif MCGMKMCH

Page 2: Leptospirosis : update on management

• Zoonotic disease

• Caused by the spirochete Leptospira

• Historically known as Weil’s disease

• Described in 1885 by Adolf Weil with clinical hallmarks of

splenomegaly jaundice nephritis

INTRODUCTION

Page 3: Leptospirosis : update on management

SYNONYMS

Page 4: Leptospirosis : update on management

THE CAUSATIVE BACTERIUMOrder Spirochaetales – Treponema, Borrelia, Leptospira

Family – Leptospiraceae, susceptible to heat, acid

Genus – Leptospira, 26 serogroups, 250 serovars

Pathogenic: Interrogans, Nonpathogenic: biflex

Corkscrew shaped, delicate, flexible spirochete, Gram -ve

thick, coiled, flagellate, actively motile

Page 5: Leptospirosis : update on management

EPIDEMIOLOGY

• Incidence of Leptospirosis in developing countries is 10 - 100/1,00,000 cases/year• Only four states (Kerala,Gujarat, Tamilnadu & Maharashtra) report more

than 500 cases per year• Incidence of Leptospirosis is 50 – 65 cases /100,000 per year in Andaman

and Nicobar Islands • Prevalence rate of Leptospirosis reported

• 38.1% from Calicut• 52.7% from Andaman and Nicobar Islands• 32.9% from Chennai (data from asymptomatic persons detected during sero surveys)

• Leptospirosis is grossly under reported because of lack of awareness of the disease and non availability of diagnostic tests• Last outbreak reported in Mumbai during 2015

Page 6: Leptospirosis : update on management

LIFE CYCLE

Page 7: Leptospirosis : update on management
Page 8: Leptospirosis : update on management
Page 9: Leptospirosis : update on management
Page 10: Leptospirosis : update on management

PATHOGENESIS

Page 11: Leptospirosis : update on management
Page 12: Leptospirosis : update on management
Page 13: Leptospirosis : update on management

•Clinical expression can beSubclinical infectionUndifferentiated febrile illnessWeil’s disease

• Incubation period 2-30 days (average 5-14 days)

CLINICAL FEATURES

Page 14: Leptospirosis : update on management
Page 15: Leptospirosis : update on management

• The most severe form of leptospirosis• Monophasic and fulminant• Variable combinations of jaundice, acute kidney

injury, hypotension and hemorrhage

• Pulmonary hemorrhage is the most common• Multisystem involvement occurs

WEIL’S DISEASE

Page 16: Leptospirosis : update on management
Page 17: Leptospirosis : update on management
Page 18: Leptospirosis : update on management

•High index of suspicion is critical in a setting ofAn appropriate exposure historyInfection’s protean manifestations

• Biochemical, hematological and urinalysis may suggest but are not specific for diagnosis

DIAGNOSIS

Page 19: Leptospirosis : update on management

LABORATORY TESTS

• TC / DC / ESR / Hb / Platelet count LEUCOCYTOSIS/THROMBOCYTOPENIA• Serum Bilirubin / SGOT/ SGPT / SAP• Blood Urea, Creatinine & Electrolytes HYPOKALEMIA/HYPOMAGNESEMIA• Chest X-Ray; ECG• Tests for diagnosis of Leptospirosis

• Culture for Leptospira• MAT; Sero conversion or 4 fold rise/ high titer• ELISA / MSAT• PCR

• MAT: Microscopic agglutination test• (M)SAT: Microscopic slide agglutination Test

Page 20: Leptospirosis : update on management

Dark field microscopy showing Leptospira spp.

Page 21: Leptospirosis : update on management

MAT INTERPRETATION• Titres peak late (2nd or 3rd week) but persist longer ( 5 to 10

years)• Less sensitive,Repeat samples needed• Single titre 1:100 significant criteria

• Endemic area 1:400• Non endemic area 1:100, 1:200• Serosurvey 1:50

• Repeat titre four fold rise / seroconversion

Page 22: Leptospirosis : update on management

• Leptospires can be cultured from blood and CSF during first 7-10 days

•Urine culture useful beginning in the 2nd week

•May take 2-4 weeks to be positive

•Urine cultures can remain positive for many months/years despite therapy

ISOLATION

Page 23: Leptospirosis : update on management

GUIDELINES TO DIAGNOSE

LEPTOSPIROSIS

•INDIAN GUIDELINES•WHO GUIDELINES

Page 24: Leptospirosis : update on management
Page 25: Leptospirosis : update on management
Page 26: Leptospirosis : update on management
Page 27: Leptospirosis : update on management
Page 28: Leptospirosis : update on management

• Malaria• Enteric fever• Dengue/ chikungunya• Hanta virus infection• Viral hepatitis• Influenza• Rickettsial diseases

DIFFERENTIAL DIAGNOSIS

Page 29: Leptospirosis : update on management
Page 30: Leptospirosis : update on management

TREATMENT

Page 31: Leptospirosis : update on management

SUPORTIVE TREATMENT

• Methyl Prednisolone at 1 gm daily IV for 3 days, followed by oral prednisolone at 1 mg/kg for 7 days offered benefit if given within 12 h of the onset of pulmonary manifestations

Page 32: Leptospirosis : update on management

COMPLICATIONS

• Jaundice

• AKI

• Pulmonary hemorrhage

• ARDS

• Neuroleptospirosis

• Hypotension

• Thrombocytopenia

• Myocarditis

• Ocular complications

• Hypokalemic paralysis

Page 33: Leptospirosis : update on management

LEPTOSPIROSIS IN PREGNANCY

• Fetal loss high in 1st trimester and near term mothers

• Congenital infections are rare and long-term serious effects have not been documented.• Hence, leptospirosis acquired in pregnancy is not an indication for its

termination• AMPICILLIN 500mg 6th hourly should be given

LEPTOSPIROSIS IN HIV• recovery slower than is usual for leptospirosis• residual renal impairment likely

Page 34: Leptospirosis : update on management

LEPTOSPIROSIS WITH CONCOMITANT ILLNESS

• It is important to look for alternative infections in an appropriate setting particularly if the patient does not show clinical signs of improvement despite pathogen-directed therapy for leptospirosis as dual infections like

• DENGUE• HEPATITIS E• SCRUB TYPHUS• MALARIACan coexist concurrently

Page 35: Leptospirosis : update on management

PREVENTION

Page 36: Leptospirosis : update on management
Page 37: Leptospirosis : update on management

CHEMOPROPHYLAXIS

Page 38: Leptospirosis : update on management

VACCINE ???

•No vaccine is yet available for use in humans with proven benefit..

Page 39: Leptospirosis : update on management
Page 40: Leptospirosis : update on management
Page 41: Leptospirosis : update on management

TAKE HOME MESSAGES

• Leptospirosis has a spectrum of clinical presentations, with a biphasic natural history.• Major systemic complications occur during the immune phase of the disease, which is

usually 5–10 days after infection.

• 2 major symptoms : fever and myalgia +/- Jaundice• 2 major signs : conjunctival suffusion and muscle tenderness

• Choice of diagnostic testing relies on accurate prediction of the infection. Acute disease is best detected by culture or PCR, and immune phase disease by serology.

• reducing the incidence of leptospirosis can be achieved by promoting the ‘cover-wash-clean up’ strategies to at risk individuals to reduce contact with infected animals or materials

Page 42: Leptospirosis : update on management